Anika Therapeutics, Inc. revised revenue guidance for the fiscal year 2023. For the year, the company raised its overall revenue outlook to be between $164 million to $166 million, representing growth of 5% to 6% compared to 2022, up from its previous range of $159.5 million to $163 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
25.62 USD | -0.47% |
|
-1.35% | +13.11% |
30/05 | Caligan Partners Enters into a Cooperation Agreement with Anika Therapeutics | CI |
28/05 | Anika Therapeutics Approves $40 Million Share Repurchase Program | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.11% | 382M | |
+2.87% | 94.22B | |
-4.08% | 37.76B | |
-13.94% | 32.5B | |
+73.38% | 27.75B | |
-11.46% | 16.13B | |
-1.88% | 14.19B | |
-11.67% | 11.42B | |
+190.36% | 11.06B | |
-52.61% | 9.09B |
- Stock Market
- Equities
- ANIK Stock
- News Anika Therapeutics, Inc.
- Anika Therapeutics, Inc. Revises Revenue Guidance for the Fiscal Year 2023